Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons

New Microbiologica

Volumn 34, Issue 2, 2011, Pages 109-146

  Antinori, Andrea ^a   Marcotullio, Simone ^b   Ammassari, Adriana ^a   Andreoni, Massimo ^c   Angarano, Gioacchino ^d   Carosi, Giampiero ^e   Cinque, Paola ^f   D'Arminio Monforte, Antonella ^g   Di Perri, Giovanni ^h   Ensoli, Barbara ⁱ   Ferrazzi, Enrico ^g   Galli, Massimo ^g   Mastroianni, Claudio ^j   Matteelli, Alberto ^e   Mazzotta, Francesco ^k   Moroni, Mauro ^g   Palù, Giorgio ^l   Puoti, Massimo ^m   Puro, Vincenzo ^a   Rizzardini, Giuliano ⁿ   Sagnelli, Evangelista ^o   Suter, Fredy ^p   Vella, Stefano ⁱ   Lazzarin, Adriano ^f   more..

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b Nadir Onlus Foundation   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d UNIVERSITY OF BARI   (Italy)

^e UNIVERSITY OF BRESCIA   (Italy)

^f SAN RAFFAELE HOSPITAL   (Italy)

^g UNIVERSITY OF MILAN   (Italy)

^h UNIVERSITY OF TURIN   (Italy)

ⁱ ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^j SAPIENZA UNIVERSITY OF ROME   (Italy)

^k SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^l UNIVERSITY OF PADOVA   (Italy)

^m OSPEDALE NIGUARDA CA GRANDA   (Italy)

ⁿ UNIVERSITY OF MILAN   (Italy)

^o UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^p OSPEDALI RIUNITI   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; ITALY; PRACTICE GUIDELINE; REVIEW;

ANTI-HIV AGENTS; HIV INFECTIONS; HIV-1; ITALY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79957608413     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (108)

1. ABDOOL KARIM S.S., NAIDOO K., GROBLER A.G., ET AL. (2010). Timing of initiation of antiretroviral drugs durino tuberculosis therapy. N Engl J Med. 362, 697-706.
2. AMMASSARI A., MURRI R., PEZZOTTI P., ET AL. (2001). Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J. Acquir. Immune Defic. Syndr. 28, 445-9.
3. AMMASSARI A., TROTTA M.P., MURRI R., ET AL. (2002). Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J. Acquir. Immune Defic. Syndr. S123-7.
4. ANTINORI A., AMMASSARI A., TORTI C., ET AL. (2009). Italian consensus statement on management of HIV-infected individuals with advanced disease naïve to antiretroviral therapy. Infection. 37:270-82.
5. ANTINORI A., ARENDT G., BECKER J.T., ET AL. (2007). Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 69, 1789-99.
6. ANTINORI A., CINGOLANI A., ALBA L., AMMASSARI A., SERRAINO D., CIANCIO B.C., ET AL. (2001). Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS. 15, 1483-91.
7. ANTINORI A., COZZI-LEPRI A., AMMASSARI A., ET AL. (2004). Relative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAART. Antivir. Ther. 9, 291-6.
8. ARRIBAS J.R., DELGADO R., ARRANZ A., MUÑOZ R., PORTILLA J., PASOUAU J., ET AL., OK04 STUDY GROUP. (2009). Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis. 51 (2), 147-152.
9. ARRIBAS J.R., HORBAN A., GERSTOFT J., FÄTKENHEUER G., NELSON M., CLUMECK N., PULIDO F., ET AL. (2010). The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS. 24 (2), 223-30.
10. BANGSBERG D.R., ACOSTA E.R, GUPTA R., ET AL. (2006). Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS. 20, 223-31.
11. BATTEGAY M., FLUCKIGER U., HIRSCHEL B., FURRER H. (2007). Late presentation of HIV-infected individuals. Antivir Ther. 12, 841-51.
12. BOYD M.A., SIANGPHOE U., RUXRUNGTHAM K., REISS P., MAHANONTHARIT A., LANGE J.M., ET AL. (2006). The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity. J. Antimicrob. Chemother. 57 (6), 1161-7.
13. BOWER M., WEIR J., FRANCIS N., NEWSOM-DAVIS., POWLES S., CROOK T., ET AL. (2009). The effect of HAART in 254 consecutive patients with AIDS-related Kaposi's Sarcoma. AIDS. 23, 1701-6.
14. BROWN T.T., QAQISH R.B. (2006). Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 20, 2165-74.
15. BUCCIARDINI R., FRAGOLA V., MASSELLA M., ET AL. (2007). Health-related quality of life outcomes in HIV-infected patients starting different combination regimens in a randomized multinational trial: the INITIO-QoL substudy. AIDS Res. Hum. Retroviruses. 23, 1215-22
16. BURGER D., HUGEN P., REISS P., ET AL. (2003). Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS. 17 (8), 1157-65.
17. CALMY A., FUX C.A., NORRIS R., VALLIER N., DELHUMEAU C., SAMARAS K., ET AL. (2009). Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. J. Infect. Dis. 200, 1746-54.
18. CINGOLANI A., ANTINORI A., RIZZO M.G., MURRI R., AMMASSARI A., BALDINI F., ET AL. (2002). Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS. 16 (3), 369-79.
19. CINQUE P., VAGO L., CERESA D., ET AL. (1998). Cerebrospinal fluid HIV-1 RNA levels: correlation with HIV encephalitis. AIDS (London, England). 12, 389-94.
20. CLOTET B., BELLOS N., MOLINA J.M., ET AL. (2007). Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 369 (9568), 1169-1178.
21. CONNOR E.M., SPERLING R.S., GELBER R., KISELEV P., SCOTT G., O'SULLIVAN M. J., ET AL. (1994). Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Proocol 076 Study Group. N. Engl. J. Med. 331 (18), 1173-80.
22. COOPER D.A., HEERA J., GOODRICH J., TAWADROUS M., SAAG M., DEJESUS E., CLUMECK N., ET. AL. (2010). Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis. 201 (6), 803-813.
23. CYSIQUE L.A., VAIDA F., LETENDRE S., ET AL. (2009). Dynamics of cognitive change in impaired HrV-positive patients initiating antiretroviral therapy. Neurology. 73, 342-8.
24. DAAR E., TIERNEY C., FISCHL M., ET AL. ACTG 5202: final results of ABC/3TC or TDF/FTC with either EFV or ATV/r in treatment-naive HIV-infected patients. Program and abstracts of the 17th Conference on Retroviruses and Opportunistic Infections; February 16-19, 2010; San Francisco, California. Abstract 59LB.
25. DAL MASO L., POLESEL J., SERRAINO D., LISE M., PISELLI P., FALCINI F, ET AL. (2009). Pattern of cancer risk persons with AIDS in Italy in the HAART era. Br. J. Cancer. 100, 840-7.
26. D'ARMINIO MONFORTE A., ET AL. (2008). HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS. 22, 2143-53.
27. DE CASTRO N., BRAUN J., CHARREAU I., PIALOUX G., COTTE L., KATLAMA C., ET AL. EASIER ANRS 138 STUDY GROUP. (2009). Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial. Clin. Infect. Dis. 49 (8), 1259-67.
28. DEEKS S.G., WRIN T., LIEGLER T., ET AL. (2001). Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl. J. Med. 344 (7), 472-480.
29. DE REQUENA D.G., BONORA S., CASTAGNA A., HASSON H., MARUCCO D.A., D'AVOLIO A., ET AL. (2008) Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtidebased regimens in HIV-positive patients. J. Antimicrob. Chemother. 62 (2), 384-7.
30. DE LUCA A., BUGARINI R., LEPRI A.C., PUOTI M., GIRARDI E., ANTINORI A., ET AL., ITALIAN COHORT NAIVE ANTIRETROVIRALS STUDY GROUP. (2002). Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch. Intern. Med. 162 (18), 2125-32.
31. DORENBAUM A, CUNNINGHAM CK, GELBER RD, CULNANE M, MOFENSON L, BRITTO P, ET AL. (2002). International PACTG 316 Team. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA. 288 (2), 189-98.
32. DURANT J., CLEVENBERGH P., HALFON P., DELGIUDICE P., PORSIN S., SIMONET P., ET AL. (1999). Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet. 26, 353 (9171), 2195-9. Erratum in: Lance. 354 (9184), 1128.
33. EL-SADR W.M., LUNDGREN J.D., NEATON J.D., GORDIN F., ABRAMS D., ARDUINO R.C., ET AL. (2006). CD4+ count-guided interruption of antiretroviral treatment. N. Engl. J. Med. 355, 2283-96.
34. ERON J., COOPER D., STEIGBIGEL R., ET AL. (2010). Sustained antiretroviral effect of raltegravir at week 156 in the BENCHMRK studies and exploratory analysis of late outcomes based on early virologie responses. Program and abstracts of the 17th Conference on Retroviruses and opportunistic infections. San Francisco, California, Abstract 515.
35. ERON J.J., YOUNG B., COOPER D.A., YOULE M., DEJESUS E., ANDRADE-VILLANUEVA J., ET AL. (2010). Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIVinfected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, doubleblind, randomised controlled trials. Lancet. 375 (9712): 396-407. Epub 2010 Jan 12.
36. FISHER M., MOYLE G.J., SHAHMANESH M., ORKIN C., KINGSTON M., WILKINS E., EWAN J., LIU H., EBRAHIMI R., REILLY G.; SWEET (SIMPLIFICATION WITH EASIER EMTRICITABINE TENOFOVIR) GROUP UK. (2009). A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals. J. Acquir. Immune Defic. Syndr. 51 (5), 562-568.
37. FLORIDIA M., RAVTZZA M., TAMBURRINI E., ANZIDEI G., TIBALDI C., MACCABRUNI A., ET AL. (2006). Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy. Diagnosis of HIV infection in pregnancy: data from a national cohort of pregnant women with HIV in Italy. Epidemiol Infect. 134, 1120-7.
38. FRIIS-MOLLER N., WEBER R., REISS P., THIEBAUT R., KIRK O., D'ARMINIO MONFORTE A., ET AL. (2003). Cardiovascular disease risk factors in HIV patientsassociation with antiretroviral therapy. Results from the DAD study. AIDS. 17, 1179-1193.
39. GALLANT J.E., DEJESUS E., ARRIBAS J.R., POZNIAK A.L., GAZZARD B., CAMPO R.E., ET AL., STUDY 934 GROUP. (2006). Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N. Engl. J. Med. 354 (3), 251-60.
40. GRANT R.M. (2010). Antiretroviral Agents Used by HFV-Uninfected Persons for Prevention: Pre- and Postexposure Prophylaxis. Clin Infect Dis. 50 (S3), S96-S101.
41. GREUB G., COZZI-LEPRI A. LEDERGERBER B, ET AL. (2002). Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS. 16(14), 1967-1969.
42. GRINSPOON S.K., GRUNFELD C., KOTLER D.P., CURRIER J.S., LUNDGREN J.D., DUBE M.P., ET AL. (2008). State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation. 118, 198-210.
43. GUARALDI G., ZONA S., ALEXOPOULOS N., ORLANDO G., CARLI F., LIGABUE G., ET AL. (2009). Coronary aging in HIV-infected patients. Clin. Infect. Dis. 49, 1756-62.
44. GULICK R.M., LALEZARI J., GOODRICH J., ET AL. (2008). Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med. 359 (14), 1429-1441.
45. GUPTA S.K., EUSTACE J.A., WINSTON J.A., BOYDSTUN, I.I., AHUJA TS, RODRIGUEZ RA, ET AL. (2005). Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin. Infect. Dis. 40, 1559-1585.
46. HERIDA M., LARSEN C., LOT F., LAPORTE A., DESENCLOS J.C., HAMERS F.F. (2006). Cost-effectiveness of HIV post-exposure prophylaxis in France. AIDS. 20, 1753-61.
47. HSUE P.Y., LO J.C., FRANKLIN A., BOLGER A.F., MARTIN J.N., DEEKS S.G., WATERS D.D. (2004). Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation. 109, 1603-8.
48. IPPOLITO G., PURO V, PETROSILLO N., DE CARU G. (1999). Surveillance of occupational exposure to bloodborne pathogens in health care workers: the Italian national programme. Euro Surveill. 4, 33-6.
49. IPPOLITO G, PURO V, DE CARLI G. (1993). The risk of occupational human immunodeficiency virus infection in health care workers: Italian Multicenter Study: the Italian Study Group on Occupational Risk of HIV infection. Arch. Intern. Med. 153, 1451-8.
50. KAPLAN J.E., BENSON C., HOLMES K.H., BROOKS J.T., PAU A., MASUR H. (2009). Centers for Disease Control and Prevention (CDC); National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 58, 1-207.
51. KELLEY C.F., KITCHEN C.M., HUNT P.W, RODRIGUEZ B., HECHT F.M., KITAHATA M., ET AL. (2009). Deeks SG. Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin. Infect. Dis. 48, 787-794.
52. KITAHATA M.M., GANGE S.J., ABRAHAM A.G., ET AL. (2009). Effect of early versus deferred antiretroviral therapy for HIV on survival. NEJM. 360, 1815-26.
53. LANDOVITZ R.J., CURRIER J.S. (2009). Clinical practice. Postexposure prophylaxis for HIV infection. N. Engl. J. Med. 361, 1768-75.
54. LAZZARIN A, CAMPBELL T, CLOTET B, JOHNSON M, KATLAMA C, MOLL A, ET AL. DUET-2 study group. (2007). Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 370 (9581), 39-48.
55. LAZZARIN A., CLOTET B., COOPER D., ET AL. (2003). Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N. Engl. J. Med. 348 (22), 2186-2195.
56. LEDERGERBER B., LUNDGREN J.D., WALKER A.S., ET AL. (2004). Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet. 364, 51-62.
57. LENNOX J.L., DEJESUS E., LAZZARIN A., POLLARD R.B., MADRUGA J.V., BERGER D.S., ZHAO J., ET AL. (2009). Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatmentnaive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 374 (9692), 796-806.
58. LETENDRE S., MARQUIE-BECK J., CAPPARELLI E., ET AL. (2008). Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch. Neurol. 65, 65-70.
59. LUNDGREN J.D., BATTEGAY M., BEHRENS G., DE WIT S., GUARALDI G. KATLAMA C., ET AL. (2008). European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med. 9, 72-81.
60. MAGGIOLO F., MIGLIORINO M., PIRALI A., ET AL. (2000). Duration of viral suppression in patients on stable therapy for HIV-I infection is predicted by plasma HIV RNA level after 1 month of treatment. J. Acquir. Immune Defic. Syndr. 25 (1), 36-43.
61. MAKADZANGE A.T., NDHLOVU C.E., TAKARINDA K., REID M., KURANGWA M., GONA P., HAKIM J.G. (2010). Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa. Clinical Infectious Diseases. 50 (11): 000-000 (on line publication).
62. MALLAL S., PHILLIPS E., CAROSI G., ET AL. (2008). HLA-B*5701 screening for hypersensitivity to abacavir. N Engl. J. Med. 358 (6), 568-79.
63. MANDELBROT L., LANDREAU-MASCARO A., REKACEWICZ C., BERREBI A., BÉNIFLA J.L., ET AL. (2009). Agence Nationale de Recherches sur le SIDA (ANRS) 075 Study Group. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA. 285 (16), 2083-93.
64. MARTÍNEZ E., ARRANZ J.A., PODZAMCZER D., LONCÁ; M., SANZ J., BARRAGÁN P., RIBERA E., ET AL. BICOMBO STUDY TEAM. (2009). A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression. J. Acquir. Immune Defic. Syndr. 51(3), 290-297.
65. MARTÍNEZ E., ARNAIZ J.A., PODZAMCZER D., DALMAU D., RIBERA E., DOMINGO P., KNOBEL H., ET AL. (2007). Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients. AIDS. 21 (3), 367-369.
66. MALLOLAS J., PODZAMCZER D., MILINKOVIC A., DOMINGO P., CLOTET B., RIBERA E., GUTIERREZ E, ET AL. ATAZIP STUDY GROUP. (2009). Efficacy and safety of switching from boosted Iopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study. J. Acquir. Immune Defic. Syndr. 51(1): 29-36.
67. MARTIN A., BLOCH M., AMIN J., DAVID BAKER, DAVID A., ET AL. FOR THE STEAL STUDY GROUP. (2009). Simplification of antiretroviral therapy with tenofovir/emtricitabine or abacavir/lamivudine: a randomized, 96 week trial. Clinical Infectious Diseases. 49, 1591-1601.
68. MELLORS J.W., RINALDO C.R. JR, GUPTA P., WHITE R.M., TODD J.A., KINGSLEY L.A. (1996). Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 272 (5265), 1167-70. Erratum in: Science 1997; 275 (5296), 14.
69. MILLS AM, NELSON M, JAYAWEERA D, RUXRUNGTHAM K, CASSETTI I, GIRARD PM, WORKMAN C, DIERYNCK I, SEKAR V ABEELE CV, LAVREYS L. (2009). Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS. 23 (13), 1679-88.
70. MOCROFT A., PHILLIPS A.N., FISHER M., CLUMECK N., Losso M., LAZZARIN A., ET AL., for the EuroSida Group. (2007). Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet. 370, 407-413.
71. MOCROFT A., KIRK O., GATELL J., REISS P., GARGALIANOS P., ZILMER K., ET AL. (2007). Chronic renal failure among HIV-1-infected patients. AIDS. 21, 1119-27.
72. MOYLE G.J., SABIN C.A., CARTLEDGE J., JOHNSON M., WILKINS E., CHURCHILL D., HAY P., ET AL. RAVE (RANDOMIZED ABACAVIR VERSUS VIREAD EVALUATION) GROUP UK. (2006). A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS. 20 (16), 2043-2050.
73. MOORE D.M., HOGG R.S., CHAN K., ET AL. (2006). Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological response. AIDS. 20 (3), 371-377.
74. MURRI R., AMMASSARI A., FANTONI M., ET AL. (1997). Disease-related factors associated with health-related quality of life in people with nonadvanced HIV disease assessed using an Italian version of the MOS-HIV Health Survey. J. Acquire Immune Defic. Syndr. Hum. Retroviral. 16, 350-6.
75. MUSSINI C., PEZZOTTI P., GOVONI A., ET AL. (2000). Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study. J. Infect. Dis. 181, 1635-42.
76. MUSSINI C., PEZZOTTI P., ANTINORI A., ET AL. (2003). Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immuno-deficiency virus-infected patients. Clin. Infect. Dis. 36, 645-1.
77. NOZZA S., GALU L., VISCO F., ET AL. (2010). Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor;sparing regimen for salvage therapy in HIV;infected patients with triple-class experience. AIDS. 24 (6), 924-8.
78. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1, 2009; 1-161. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
79. PARIENTI J.J., BANGSBERG D.R., VERDON R. (2009). Better adherence with once-daily antiretroviral regimens: a meta-analysis. Clin. Infect. Dis. 48 (4), 484-8.
80. PINKERTON S.D., MARTIN J.N., ROLAND M.E., KATZ M.H., COATES T.J., KAHN J.O. (2004). Cost-effectiveness of post-exposure prophylaxis after sexual or injectiondrug exposure to human immunodeficiency virus. Arch. Intern. Med. 164, 46-54.
81. POWER C., SELNES O.A., GRIM J.A., MCARTHUR J.C. (1995) HIV Dementia Scale: a rapid screening test. J. Acquir. Immune Defic. Syndr. Hum. Retroviral. 8, 273-8.
82. PRICE R.W., EPSTEIN L.G., BECKER J.T., ET AL. (2007). Biomarkers of HIV-1 CNS infection and injury. Neurology. 69, 1781-8.
83. PUBLIC HEALTH SERVICE TASK FORCE RECOMMENDATIONS FOR USE OF ANTIRETROVIRAL DRUGS IN PREGNANT HIV-INFECTED WOMEN FOR MATERNAL HEALTH AND INTERVENTIONS TO REDUCE PERINATAL HIV TRANSMISSION IN THE UNITED STATES. April 29, 2009. Available at: http://www.aidsinfo.nih.gov/Guidelines/GuidelineDetail. aspx?GuidelineID=9
84. RIDDLER S.A., HAUBRICH R., DIRIENZO A.G., PEEPLES L., POWDERLY W.G., KLINGMAN K.L., ET AL. AIDS CUNICAL TRIALS GROUP STUDY A5142 TEAM. (2008). Class-sparing regimens for initial treatment of HIV-1 infection. N Engl. J. Med. 358 (20), 2095-106.
85. ROCKSTROH J.K., BHAGANI S., BENHAMOU Y., BRUNO R., MAUSS S., PETERS L., PUOTI M., ET AL. (2008). European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV infected adults. HIV Med. 9 (2), 82-8.
86. SACKTOR N.C., WONG M., NAKASUJJA N., ET AL. (2005). The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS (London, England). 19, 1367-74.
87. SAX P.E., ISLAM R., WALENSKY R.P., LOSINA E., WEINSTEIN M.C., GOLDIE S.J., ET AL. (2005). Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin. Infect. Dis. 41 (9), 1316-23. Epub 2005 Sep 23.
88. SAX P.E., TIERNEY C., COLLIER A.C., ET AL. (2009). Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N. Engl. J. Med. 361, 2230-2240.
89. SIMIONI S., CAVASSINI M., ANNONI J.M., ET AL. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS (London, England) 2009.
90. SMITH D.E., WALKER B.D., COOPER D.A., ROSENBERG E.S., KALDOR J.M. (2004). Is antiretroviral treatment of primary HIV infection clinically justified on the basis of current evidence? AIDS. 18 (5), 709-718.
91. SMITH K.Y., PATEL P., FINE D., BELLOS N., SLOAN L., LACKEY P., KUMAR P.N., ET AL., HEAT Study Team. (2009). Randomized, double-blind, placebomatched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS. 23 (12), 1547-56.
92. SORIANO V., PERNO C.F., KAISER R., ET AL. (2009). When and how to use maraviroc in HIV-infected patients. AIDS. 23, 2377-2385.
93. SORIANO V., PUOTI M., SULKOWSKI M., CARGNEL A., BENHAMOU Y., PETERS M., ET AL. (2007). Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS. 21 (9), 1073-89.
94. SORIANO V., PUOTI M., PETERS M., BENHAMOU Y., SULKOWSKI M., ZOULIM F., ET AL. (2008). Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS. 22 (12), 1399-410.
95. STEIGBIGEL R.T., COOPER D.A., KUMAR P.N., ET AL. (2008). Raltegravir with optimized background therapy for resistant HIV-1 infection. N. Engl. J. Med. 359 (4), 339-354.
96. STERNE J.A., MAY M., COSTAGLIOLA D., ET AL. (2009). Timing of initiation of antiretroviral therapy in AIDS-free HIV-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 373, 1352-1363.
97. THE COLLABORATION OF OBSERVATIONAL HIV EPIDEMIOLOGICAL RESEARCH EUROPE (COHERE) STUDY GROUP. (2008). Response to combination antiretroviral therapy: variation by age. AIDS. 22, 1463-73.
98. THE COLLABORATION OF OBSERVATIONAL HIV EPIDEMIOLOGICAL RESEARCH EUROPE (COHERE) STUDY GROUP. (2009). Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. AIDS. 23, 2029-2037.
99. TOZZI V., BALESTRA P., BELLAGAMBA R., ET AL. (2007). Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. Journal of acquired immune deficiency syndromes. 45, 174-82.
100. TURAL C., RUIZ L., HOLTZER C., SHAPIRO J., VICIANA P., GONZALEZ J., ET AL. (2002). Clinical utility of HIV-1 genotyping and expert advice: the Havana Trial. AIDS. 16, 209-218.
101. VACCHER E., SPINA M., TALAMINI R., ZANETTI M., DI GENNARO G., NASTI G., ET AL. (2003). Improvement of systemic human immunodeficiency virus-related non-Hodgkin lymphoma outcome in the era of highly active antiretroviral therapy. Clin. Infect. Dis. 37, 1556-64.
102. VALCOUR V., SHIKUMA C., SHIRAMIZU B., ET AL. (2004). Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort. Neurology. 63, 822-7.
103. VAN LETH F., PHANUPHAK P., RUXRUNGTHAM K., BARALDI E., MILLER S., GAZZARD B., CAHN P., ET AL., 2NN STUDY TEAM. (2004). Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet. 363 (9417): 1253-1263.
104. WATERS L., MANDALIA S., ASBOE D. (2006). Successful use of genotypic resistance testing in HIV-1-infected individuals with detectable viraemia between 50 and 1000 copies/ml. AIDS. 20 (5), 778-779.
105. WORM S.W., SABIN C., WEBER R., REISS P., EL-SADR W., DABIS E, ET AL. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIVdrugs (D:A:D) study. J. Infect. Dis. 201, SIS-30.
106. YAZDANPANAH Y., FAGARD C., DESCAMPS D., ET AL. (2009). ANRS 139 TRIO Trial Group High rate of virologie suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin. Infect. Dis. 49 (9), 1441-9.
107. ZANONE POMA B., RIVA A., NASI M., CICCONI P., BROGGINI V., LEPRI A.C., ET AL., ICONA FOUNDATION STUDY GROUP. (2008). Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy. AIDS. 22 (14), 1769-78
108. ZOLOPA A., ANDERSEN J., POWDERLY W., SANCHEZ A., SANNE I., SUCKOW C., ET AL. (2009). Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One. 4: e5575.